aBLA Filing Intelligence & Biosimilar Opportunity

Tevimbra

Tislelizumab-Jsgr

Anticancer

IV Injection

Tevimbra contains Tislelizumab, a monoclonal antibody that is indicated for the treatment of unresectable or metastatic small-cell lung cancer and gastric adenocarcinoma in adult patients. It can be given as a first line in combination with other chemotherapeutic agents, and also to patients who have previously received chemotherapy.

Approval Date

13-Mar-24

Data Exclusivity Expiry

13-Mar-28

Market Exclusivity Expiry

13-Mar-36

Commercial snapshot

Market performance & projections

Revenue ($M)

737

CAGR (%)

14.60%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

851

2027

999

2028

1,144

2029

1,271

2030

1,380

2031

1,481

2032

1,577

Molecule profile

Details & specifications

Molecule

Tislelizumab-Jsgr

Innovator

BEIGENE, LTD.

Dosage Form

IV Injection

Strength

100 mg/10 mL

Therapeutic Category

Anticancer

Usage

To treat unresectable or metastatic esophageal squamous cell carcinoma

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets